Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group

Journal of Bone and Mineral Research

Volumn 11, Issue 10, 1996, Pages 1492-1497

  Van Beek, Ermond ^a   Löwik, Clemens ^a   Que, Ivo ^a   Papapoulos, Socrates ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM OXALATE; ETIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; BONE GROWTH; BONE MINERAL; CRYSTALLIZATION; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; EXPLANT; FETUS; LONG BONE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; STRUCTURE ACTIVITY RELATION;

EID: 0029782286     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.5650111016     Document Type: Article

References (25)

1. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ 1994 Bisphosphonates: Structure-activity relationships and therapeutic implications. In: Heersche JNM, Kanis JA (eds.) Bone and Mineral Research/8. Elsevier Science BV, Amsterdam, The Netherlands, pp. 265-306.
2. Fleisch H 1991 Bisphosphonates: Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs 42:919-944.
3. Papapoulos SE 1993 The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 95 (5A):48-52.
4. Benedict JJ 1982 The physical chemistry of the disphosphonates - its relationship to their medical activity. In: Donath A, Courvoisier B (eds.) Disphosphonates and Bone. Symposium CEMO IV, Nyon, Switzerland, Editions Medecine et Hygiene, Geneva, pp. 1-19.
5. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P 1983 Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87-99.
6. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA 1989 Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 15:389-396.
7. Ebetino FH, Kaas SM, Crawford RJ 1993 Bisphosphonates: Molecular modelling, structure-activity relationships and the rational design of new analogs. Phosphorus Sulfur Silicon 76:151-154.
8. Rogers J, Xiong X, Brown RJ, Watts DJ, Russel GG, Bayless AV, Ebetino FH 1995 Structure-activity relationships of new hetrocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoeba. Mol Pharmacol 47:398-402.
9. van Beek E, Hoekstra M, van de Ruit M, Löwik C, Papapoulos S 1994 Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9:1875-1882.
10. Sunberg R, Ebetino FH, Mosher CT, Roof CF 1991 Designing drugs for stronger bones. Chemtech 21:304-309.
11. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Thesingh CW, Bijvoet OLM 1986 Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1:27-39.
12. Papapoulos SE, Hoekman K, Löwik CWGM, Vermij P, Bijvoet OLM 1989 Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 5:775-781.
13. van der Pluijm G, Most W, van der Wee-Pals L, de Groot H, Papapoulos S, Löwik C 1991 Two distinct effects of recombinant human tumor necrosis factor-α on osteoclast development and subsequent resorption of mineralized matrix. Endocrinology 129:1596-1604.
14. Burger EH, van der Meer JWM, van de Gevel JS, Gribnau JC, Thesingh CW, van Furth, R 1982 In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J Exp Med 156:1604-1615.
15. van Beek E, van der Wee-Pals L, van de Ruft M, Nijweide P, Papapoulos S, Löwik C 1993 Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization, and alkaline phosphatase activity in fetal mouse metacarpal bones in culture. J Bone Miner Res 8:191-197.
16. Klein-Nulend J, Veldhuizen JP, Burger EH 1986 Increased calcification of growth plate cartilage as a result of compressive force in vitro. Arthr Rheum 29:1002-1009.
17. Kok DJ, Papapoulos SE, Blomen LJMT, Bijvoet OLM 1988 Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int 34:346-350.
18. Schenk R, Eggli H, Fleisch H, Rosini S 1986 Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349.
19. Boonekamp PM, Löwik CWGM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Bijvoet OLM 1987 Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner 2:29-42.
20. Russel RGG, Muhlbaur RC, Bisaz S, Williams DA, Fleisch H 1970 The influence of phosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 6:183-196.
21. Rogers MJ, Watts DJ, Russel GG, Xiaohuil JI, Xiong X, Blackburn GM, Bayless AV, Ebetino F 1994 Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. J Bone Miner Res 9:1029-1039.
22. Sietsema WK, Ebetino HE 1994 Bisphosphonates in development for metabolic bone disease. Exp Opin Invest Drugs 3(12): 1255-1276.
23. Ibbotson KJ, D'Souza SM, Bayless A, Ebrahimpour A, Ebetino FH, Woodiel FN, Fall PE, Raisz LG 1994 The phosphonate moieties of bisphosphonates are more than just a targeting function: Evidence from the study of bisphosphonate analogues in vitro. Bone Miner 25 (Suppl 1):S66.
24. Ebrahimpour A, Ruble A, Ebetino F 1994 The physicochemical interaction of a bisphosphonate (bp), a conformationally restricted bp, and a phosphonoalkylphosphinate (pap), with bone minerals. J Bone Miner Res 9 (Suppl 1):S247.
25. Shani M, Guenther HL, Fleisch H, Collin P, Martin TJ 1993 Bisphosphonates act on rat bone through the mediation of osteoblasts. J Clin Invest 91:2004-2011.